Olink Target 96 Immuno-Oncology

The right choice for targeted protein biomarker discovery in immuno-oncology applications

Please note that the information here refers to the latest version of this panel (article number 95311), released on June 13, 2019. This includes a number of assay changes and improvements compared to the previous version – see more here.

Immunotherapy is one of the most exciting and rapidly developing approaches to cancer therapy. Strategies that aim to strengthen the patients’ own immune system to fight tumor cells and to break tolerance in the tumor microenvironment are beginning to show great promise. There have been several successful clinical trials reported and some successes dealing with several types of tumors in patients with poor prognosis, with checkpoint inhibitors emerging as one particularly promising class of new drugs for this area.

The Immuno-Oncology panel is a high-throughput, multiplex immunoassay enabling analysis of 92  protein biomarkers across 96 samples simultaneously. This high level of multiplexing is achieved without any compromise on data quality, thanks to our proprietary Proximity Extension Assay (PEA) technology

Non-invasive biomarkers for the immuno-oncology area offer great potential benefits in helping to better understand the underlying pathophysiology, study therapeutic efficacy and to stratify patients for clinical trials. This panel provide the immuno-oncology field with a tool that casts a relatively broad net (simultaneous analysis of 92 proteins), while enabling a targeted approach via the careful selection of relevant assays available. The biomarkers selected in consultation with experts in the field include proteins involved in processes such as promotion and inhibition of tumor immunity, chemotaxis, vascular & tissue remodeling, apoptosis & cell killing and metabolism & autophagy.

An overview of how the 92 biomarker assays in the panel are classified according to Biological Process, Disease Area, Tissue Expression and Protein Class (based on widely used public-access bioinformatic databases, including Uniprot, Human Protein Atlas, Gene Ontology (GO) and DisGeNET) can be seen in the charts below. These charts are interactive: click on a chart-bar or pie-segment to see the list of biomarkers in that classification. Each item in the list links to the detailed biomarker page with validation data. Please note that these classifications are intended for general guidance only and while correct at the time of publication, they are not updated in real-time and you are advised to always check the source databases in order to see the latest updates regarding the information for specific proteins.

Biological Process

Note that while based on Gene Ontology biological process terms, the categories shown here have been aggregated to reflect areas of key interest in the immuno-oncology field.

Disease Area

Tissue Expression

Protein Class

A comprehensive list of all protein biomarkers that can be measured using the currently available Olink panels can be seen on the biomarker library page.

Note: A printable list of the biomarker assays available in this panel, as well as a full data validation document, can be downloaded from our Document download center >>

If you prefer not to run the assay yourself, let our experts here at Olink do this for you via our Olink Analysis Service.

The biomarker pages linked to below include calibrator curves that show the performance of each assay with the estimated sensitivity and dynamic range parameters indicated. These curves are generated during the assay validation process using recombinant antigens, with data presented as Normalized Protein eXpression (NPX) values plotted against protein concentration (in pg/mL). Please note that when analyzing biological samples the data generated will be given in the form of relative quantification (NPX values) and cannot be converted to absolute protein concentrations. For more info about NPX measurements, please view the FAQ.

Please note: Four assays were replaced and two were substantially improved for the current version of the panel (see details). Although these assays were subject to rigorous validation & QC during their development, final validation data in full-panel context is not yet available. This will be updated as soon as possible.